Cytokinetics, Incorporated · NASDAQ:CYTK

Callos Andrew sold 15,000 Cytokinetics, Incorporated shares (Form 4)

Traded Apr 30, 2026 · Filed Apr 30, 2026

On Apr 30, 2026, Callos Andrew (EVP, Chief Commercial Officer) sold 15,000 Cytokinetics, Incorporated shares at US$63.26 for US$949K under a trading plan, leaving 58,555 shares. Filed Apr 30, 2026 (Form 4).

Sold
15,000 shares
Price
US$63.26
Value
US$949K
Holding after
58,555 shares
Trading plan
Yes (Made under a plan set in advance)
Role
EVP, Chief Commercial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 30, 2026Common StockOption exercise15,000US$23.2673,555Direct
Apr 30, 2026Common StockSale15,000US$63.2658,555Direct

Source

View original at SEC

Related